The management of herpes simplex virus infections

Current Opinion in Infectious Diseases

Volumn 15, Issue 2, 2002, Pages 115-122

  Yeung Yue, Kimberly A ^a   Brentjens, Mathijs H ^a   Lee, Patricia C ^a   Tyring, Stephen K ^a  

^a UTMB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; CIDOFOVIR; FAMCICLOVIR; FOSCARNET; HERPES SIMPLEX VACCINE; PENCICLOVIR; RESIQUIMOD; VALACICLOVIR;

ANEMIA; CLINICAL TRIAL; DISTRESS SYNDROME; DRUG INDUCED DISEASE; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HERPES SIMPLEX; HERPES SIMPLEX VIRUS; HUMAN; INFECTION PREVENTION; NEPHROTOXICITY; PERSISTENT VIRUS INFECTION; REVIEW; VIRUS INHIBITION; VIRUS REPLICATION;

ANTIVIRAL AGENTS; HERPES SIMPLEX; HERPES SIMPLEX VIRUS VACCINES; HUMANS; SIMPLEXVIRUS;

EID: 0036218560     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-200204000-00003     Document Type: Review

References (78)

1. Viral disease update
2. The heterogeneous clinical spectrum of genital herpes
3. Herpes simplex: Evolving concepts
4. Cold sores: A new understanding of their pathophysiology and the need for a new treatment
5. The current trend in genital herpes. Progress in prevention
6. Recurrences after oral and genital herpes simplex virus infection. Influence of site of infection and viral type
7. Herpes simplex viruses
8. Sero-epidemiological and sociological patterns of herpes simplex virus infection in the world
9. Herpes simplex virus type 2 in the United States, 1976 to 1994
10. Recurrence rates in genital herpes after symptomatic first-episode infection
11. Herpes simplex virus type 1 as a cause of genital herpes: Impact on surveillance and prevention
12. A prospective study of new infections with herpes simplex virus type 1 and type 2
13. Herpes. Atypical clinical manifestations
14. Risk of recurrence after first episodes of genital herpes. Relation to HSV type and antibody response
15. Virologic characteristics of subclinical and symptomatic genital herpes infections
16. Risk factors for the sexual transmission of genital herpes
17. Frequent genital herpes simplex virus 2 shedding in immunocompetent women. Effect of acyclovir treatment
18. Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons
19. The importance of diagnosing genital herpes
20. Herpes serology for dermatologists
21. Diagnosing genital ulcer disease in a clinic for sexually transmitted diseases in Amsterdam, The Netherlands
22. Identification of herpes simplex virus genital infection: Comparison of a multiplex PCR assay and traditional viral isolation techniques
23. Sorting out the new HSV type specific antibody tests
24. Treatment of common cutaneous herpes simplex virus infections
25. Evaluation of a novel point of care test for antibodies to herpes simplex virus type 2
26. Premarket evaluation of the POCkit HSV-2 type-specific serologic test in culture-documented cases of genital herpes simplex virus type 2
27. An evaluation of near patient tests for detecting herpes simplex virus type-2 antibody
28. Management of neonatal herpes simplex virus infection
29. Genital herpes complicating pregnancy
30. Natural history of neonatal herpes simplex virus infections in the acyclovir era
31. Genital herpes and public health: Addressing a global problem
32. Epidemiological synergy. Interrelationships between human immunodeficiency virus infection and other sexually transmitted diseases
33. Prior herpes simplex virus type 2 infection as a risk factor for HIV infection
34. The association between genital ulcer disease and acquisition of HIV infection in homosexual men
35. Herpes simplex virus infection as a risk factor for human immunodeficiency virus infection in heterosexuals
36. Co-infection and synergy of human immunodeficiency virus-1 and herpes simplex virus-1
37. Direct recovery of herpes simplex virus (HSV) specific T lymphocyte clones from recurrent genital HSV-2 lesions
38. Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men
39. The impact of active herpes simplex virus infection on human immunodeficiency virus load
40. From epidemiological synergy to public health policy and practice: The contribution of other sexually transmitted diseases to sexual transmission of HIV infection
41. Herpes simplex virus infection induces replication of human immunodeficiency virus type 1
42. Herpes simplex virus shedding and plasma human immunodeficiency virus RNA levels in coinfected women
43. Thymidine kinase from herpes simplex virus phosphorylates the new antiviral compound, 9-(2-hydroxyethoxymethyl)guanine
44. Acyclovir triphosphate is a suicide inactivator of the herpes simplex virus DNA polymerase
45. Genvir (Flamel Technologies)
46. Prophylactic chemotherapy with acyclovir for recurrent herpes simplex labialis
47. Treatment of recurrent herpes simplex labialis with oral acyclovir
48. Oral acyclovir to suppress frequently recurrent herpes labialis. A double-blind, placebo-controlled trial
49. Peroral famciclovir in the treatment of experimental ultraviolet radiation-induced herpes simplex labialis: A double-blind, dose-ranging, placebo-controlled, multicenter trial
50. Famciclovir in the management of first-episode genital herpes
51. Prolonged continuous acyclovir treatment of normal adults with frequently recurring genital herpes simplex virus infection
52. Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir
53. Acyclovir suppression to prevent clinical recurrences at delivery after first episode genital herpes in pregnancy: An open-label trial
54. Acyclovir prophylaxis in late pregnancy prevents recurrent genital herpes and viral shedding
55. Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections
56. A risk-benefit evaluation of aciclovir for the treatment and prophylaxis of herpes simplex virus infections
57. Valaciclovir: A review of its long term utility in the management of genital herpes simplex virus and cytomegalovirus infections
58. Famciclovir vs. aciclovir in immunocompetent patients with recurrent genital herpes infections: A parallel-groups, randomized, double-blind clinical trial
59. Renal function after acyclovir intravenous injection
60. Application of a topical immune response modifier, resiquimod gel, to modify the recurrence rate of recurrent genital herpes: A pilot study
61. New therapy promising for genital herpes
62. Antivirai therapy of herpes simplex
63. Multicenter collaborative trial of intravenous acyclovir for treatment of mucocutaneous herpes simplex virus infection in the immunocompromised host
64. Intravenous penciclovir for treatment of herpes simplex infections in immunocompromised patients: Results of a multicenter, acyclovir-controlled trial
65. Sequential intravenous and twice-daily oral acyclovir for extended prophylaxis of herpes simplex virus infection in marrow transplant patients
66. Efficacy and safety of famciclovir for the treatment of HSV infection in HIV+ patients
67. Famciclovir for the suppression of symptomatic and asymptomatic herpes simplex virus reactivation in HIV-infected persons. A double-blind, placebo-controlled trial
68. Survey of resistance of herpes simplex virus to acyclovir in northwest England
69. Brief report: Recurrent acyclovir-resistant genital herpes in an immunocompetent patient
70. Herpes simplex virus antiviral drug resistance: Current trends and future prospects
71. Current recommendations for the treatment of genital herpes
72. Frequency of acyclovir-resistant herpes simplex virus in clinical specimens and laboratory isolates
73. Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women
74. Prospects for control of herpes simplex virus disease through immunization
75. Herpes simplex virus DNA vaccine efficacy: Effect of glycoprotein D plasmid constructs
76. Plasmid DNA-expressed secreted and nonsecreted forms of herpes simplex virus glycoprotein D2 induce different types of immune responses
77. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: Two randomized controlled trials
78. Genital herpes vaccine shows limited promise